FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555849348> ?p ?o ?g. }

• W2555849348 abstract "Abstract Abstract 4561 Chronic myelomonocytic leukemia (CMML) typically has a dire prognosis with limited treatment options. We retrospectively reviewed the outcomes of 41 patients diagnosed with CMML (n= 35) or MDS/MPD overlap (n=6) who underwent allogeneic stem cell transplantation at three centers (University of Minnesota (n= 19), Johns Hopkins University (n=11), and the Cleveland Clinic (n=11)) between1990-2009. The majority of patients were male (59%) with a mean age of 51. At diagnosis nearly half of the patients had normal cytogenetics (n=20, 49%) with abnormalities of chromosome 7 the most commonly identified clonal finding (n=5, 12%). The majority had <5% blasts (n=22, 54%), and the majority had an MD Anderson Prognostic Score (MDAPS) of 2 (n=16, 39%) or 3 (n=13, 32%) at diagnosis. Fifteen patients (37%) received no pre-transplant therapy while 12 (29%) received hydroxyurea, 11 (27%) induction-type chemotherapy, and 3 (7%) miscellaneous other therapies. Nine patients (22%) had progressed to AML prior to transplant. At the time of transplant, blast percentage was <5% in the majority (n=23, 56%) of patients and more than half of patients now had a MDAPS of 1 (n=13, 32%) or 2 (n=12, 32%). Comorbidity index (HCT-CI) at transplant was retrospectively calculated on 32 patients and was 0 (n=5, 12%), 1–2 (n=13, 32%), or 3+ (n= 15, 37%). Myeloablative conditioning was used in 23 (56%) and stem cell source was bone marrow in 14 (34%), PBSC in 16 (39%), and UCB in 9 (22%). The majority of donors were matched siblings (n=22, 54%) while unrelated donors (URD) (n=16, 39%) and haploidentical donors (n=3, 7%) comprised the remaining. Graft versus host disease (GVHD) prophylaxis consisted of a calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate or mycophenolate mofetil (MMF) in the majority of patients (n=29, 71%) with the remainder receiving post-transplant cyclophosphamide (n=6, 15%), elutriation (n=2, 5%), or calcineurin inhibitor alone (n=4, 10%). While the median time to follow-up was only 5.8 months (range 0.5–140), 24 patients had died by one year and there was extensive follow-up available in the surviving patients. Overall survival (OS) for the entire cohort at 1 and 3 years was 41% (95% CI, 26–56%) and 16% (95% CI, 6–30%), respectively. No disease or transplant factors significantly impacted survival. Progression free survival (PFS) at 1 and 3 years was 29% (95% CI, 16–43%) and 16% (95% CI, 7–29%), respectively. Sibling donor showed improved PFS at both 1 (45%, 95% CI 24–64%), (p=0.027) and 3 (27%, 95% CI 10–46%), (p=0.04) years. Transplant related mortality (TRM) at Day +100 and 1 year was 27% (95% CI, 13–40%) and 41% (95% CI, 26–57%) respectively. Age at transplant, year transplanted, HCT-CI at transplant, conditioning intensity, donor source, transplant site, or presence of acute graft versus host disease (GVHD) did not impact TRM. Relapse at 1 and 3 years was 29% (95% CI, 15–44%) and 40% (95% CI, 23–56%), respectively. High MDAPS at diagnosis and sibling donor source were the only significant factors impacting relapse. At 1 year, those with an MDAPS of 3–4 had a 53% chance of relapse compared with 29% with a score of 0–1 (p=0.05) and those with a sibling donor had a 9% relapse incidence compared with 50% in the URDs and 67% in the haploidentical setting (p=0.003). Interestingly the presence of acute GVHD at Day +100 was not protective against relapse (40% incidence at 1 year in those with aGVHD versus only 19% for those without). Our data suggest that high MD Anderson Prognostic score at diagnosis predicts for high incidence of relapse post allogeneic stem cell transplantation while a sibling donor source improves rates of relapse and progression free survival. Our data highlight the need for improved CMML treatment paradigms. Augmentation of pre and post transplant therapy including maintenance therapy post transplant are possible approaches to improve outcomes and could be considered for prospective trials. Disclosures: No relevant conflicts of interest to declare." @default.
• W2555849348 created "2016-11-30" @default.
• W2555849348 creator A5003078712 @default.
• W2555849348 creator A5011655907 @default.
• W2555849348 creator A5061692821 @default.
• W2555849348 creator A5069092267 @default.
• W2555849348 creator A5077292257 @default.
• W2555849348 creator A5078527108 @default.
• W2555849348 creator A5085974329 @default.
• W2555849348 creator A5086664284 @default.
• W2555849348 date "2010-11-19" @default.
• W2555849348 modified "2023-09-26" @default.
• W2555849348 title "Chronic Myelomonocytic Leukemia and Related Disorders Provide Particular Disease-Specific Challenges to Effective Bone Marrow Transplant: a Multicenter Experience." @default.
• W2555849348 doi "https://doi.org/10.1182/blood.v116.21.4561.4561" @default.
• W2555849348 hasPublicationYear "2010" @default.
• W2555849348 type Work @default.
• W2555849348 sameAs 2555849348 @default.
• W2555849348 citedByCount "0" @default.
• W2555849348 crossrefType "journal-article" @default.
• W2555849348 hasAuthorship W2555849348A5003078712 @default.
• W2555849348 hasAuthorship W2555849348A5011655907 @default.
• W2555849348 hasAuthorship W2555849348A5061692821 @default.
• W2555849348 hasAuthorship W2555849348A5069092267 @default.
• W2555849348 hasAuthorship W2555849348A5077292257 @default.
• W2555849348 hasAuthorship W2555849348A5078527108 @default.
• W2555849348 hasAuthorship W2555849348A5085974329 @default.
• W2555849348 hasAuthorship W2555849348A5086664284 @default.
• W2555849348 hasConcept C104317684 @default.
• W2555849348 hasConcept C126322002 @default.
• W2555849348 hasConcept C138626823 @default.
• W2555849348 hasConcept C143998085 @default.
• W2555849348 hasConcept C174475383 @default.
• W2555849348 hasConcept C2777928532 @default.
• W2555849348 hasConcept C2778461978 @default.
• W2555849348 hasConcept C2778904597 @default.
• W2555849348 hasConcept C2779134260 @default.
• W2555849348 hasConcept C2780007613 @default.
• W2555849348 hasConcept C2780817109 @default.
• W2555849348 hasConcept C28328180 @default.
• W2555849348 hasConcept C2911091166 @default.
• W2555849348 hasConcept C2994180119 @default.
• W2555849348 hasConcept C30481170 @default.
• W2555849348 hasConcept C54355233 @default.
• W2555849348 hasConcept C71924100 @default.
• W2555849348 hasConcept C86803240 @default.
• W2555849348 hasConceptScore W2555849348C104317684 @default.
• W2555849348 hasConceptScore W2555849348C126322002 @default.
• W2555849348 hasConceptScore W2555849348C138626823 @default.
• W2555849348 hasConceptScore W2555849348C143998085 @default.
• W2555849348 hasConceptScore W2555849348C174475383 @default.
• W2555849348 hasConceptScore W2555849348C2777928532 @default.
• W2555849348 hasConceptScore W2555849348C2778461978 @default.
• W2555849348 hasConceptScore W2555849348C2778904597 @default.
• W2555849348 hasConceptScore W2555849348C2779134260 @default.
• W2555849348 hasConceptScore W2555849348C2780007613 @default.
• W2555849348 hasConceptScore W2555849348C2780817109 @default.
• W2555849348 hasConceptScore W2555849348C28328180 @default.
• W2555849348 hasConceptScore W2555849348C2911091166 @default.
• W2555849348 hasConceptScore W2555849348C2994180119 @default.
• W2555849348 hasConceptScore W2555849348C30481170 @default.
• W2555849348 hasConceptScore W2555849348C54355233 @default.
• W2555849348 hasConceptScore W2555849348C71924100 @default.
• W2555849348 hasConceptScore W2555849348C86803240 @default.
• W2555849348 hasLocation W25558493481 @default.
• W2555849348 hasOpenAccess W2555849348 @default.
• W2555849348 hasPrimaryLocation W25558493481 @default.
• W2555849348 hasRelatedWork W125375142 @default.
• W2555849348 hasRelatedWork W1995609278 @default.
• W2555849348 hasRelatedWork W1995811536 @default.
• W2555849348 hasRelatedWork W1996329322 @default.
• W2555849348 hasRelatedWork W2019197970 @default.
• W2555849348 hasRelatedWork W2020460142 @default.
• W2555849348 hasRelatedWork W2054986003 @default.
• W2555849348 hasRelatedWork W2068835074 @default.
• W2555849348 hasRelatedWork W2079319641 @default.
• W2555849348 hasRelatedWork W2312381856 @default.
• W2555849348 hasRelatedWork W2409723000 @default.
• W2555849348 hasRelatedWork W2436885231 @default.
• W2555849348 hasRelatedWork W2437154163 @default.
• W2555849348 hasRelatedWork W2442246503 @default.
• W2555849348 hasRelatedWork W2460780174 @default.
• W2555849348 hasRelatedWork W2473497944 @default.
• W2555849348 hasRelatedWork W2949283591 @default.
• W2555849348 hasRelatedWork W3043391528 @default.
• W2555849348 hasRelatedWork W3134581256 @default.
• W2555849348 hasRelatedWork W3160665527 @default.
• W2555849348 isParatext "false" @default.
• W2555849348 isRetracted "false" @default.
• W2555849348 magId "2555849348" @default.
• W2555849348 workType "article" @default.